ENDRA Life Sciences Pivots with Noble Africa Merger, Secures $50M Capital Infusion
NDRA sits 98% above its 52-week low of $2.96.
Summary
ENDRA Life Sciences announced a proposed merger of its subsidiary with Noble Africa, a helium company, alongside a planned $50 million private placement. This transformative event provides a critical lifeline for ENDRA, which has been facing a Nasdaq delisting notice, a going concern warning, and critically low cash balances. While the $50 million capital raise is substantial, representing nearly seven times ENDRA's current market cap, existing shareholders will be significantly diluted, owning only approximately 3% of the combined entity. This news follows 8-K and 425 filings from today confirming the transaction. The deal is expected to close in Q3 or Q4 2026, pending SEC registration and shareholder approval.
At the time of this announcement, NDRA was trading at $5.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $2.96 to $11.96. This news item was assessed with positive market sentiment and an importance score of 10 out of 10. Source: Wiseek News.